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Abstract
Background: Past studies have reported conflicting results regarding the association between
acetaminophen use during pregnancy and the risk of developing childhood asthma.
Objectives: To perform an updated review on past studies investigating the association between
prenatal acetaminophen use and the risk of developing asthma within the first ten years of life.
Methods: A systematic review and meta-analysis was conducted using PubMed search (1950December 1, 2011) to identify studies that investigated the association between intrauterine
exposure to acetaminophen and childhood asthma. Inclusion criteria consisted of a study design
restricted to prospective cohort studies, primary exposure of acetaminophen intake during
pregnancy, and primary outcome of physician-diagnosed asthma or a combination of two of the
following indicators of asthma (use of asthma medication, hospitalization due to asthmatic
symptoms, wheezing, and ER visits due to wheezing). Study quality was assessed and data was
extracted by one reviewer. An inverse variance fixed-effects model was used, and adjusted odds
ratio was calculated to compare effect sizes of studies.
Results: The review comprised of six studies: two studies assessed physician-diagnosed asthma
among children under the age of 2 years and four studies ascertained asthma outcome between the
ages 2 and 10 years. The overall pooled estimate calculated from all six studies was 1.12 (95%CI:
1.03, 1.22). Children whose asthma status was recorded before the age of 2 had an overall pooled
aOR of 1.18 [95%CI:1.13,1.23] while children between the ages of 2 and 10 years had a pooled aOR
of 1.13[95%CI:1.01, 1.26]. For studies that did a follow-up among children under the age of 2 years,
subgroup analyses of acetaminophen exposure during different stages of pregnancy displayed
consistent statistically significant associations between prenatal acetaminophen use and childhood
asthma. The subgroup analysis of different stages of pregnancy for studies that reported asthma
outcome among children older than 2 years of age showed that risk of childhood asthma was only
associated with intrauterine exposure to acetaminophen during the later stages of pregnancy
(aOR[95%CI]: 1.23[1.08, 1.42]). There was not enough information to verify a dose-response
relationship.
Conclusions: The findings support a modest association of exposure to prenatal acetaminophen
use with childhood asthma development. By reviewing only prospective studies, we established
temporality, thus further strengthening our hypothesis that acetaminophen use during pregnancy
causes an increased risk of childhood asthma. Further studies need to be conducted to confirm this
association, and specify the dose, frequency and trimester use of acetaminophen.
(Word count 398)

Background
Asthma is a chronic inflammatory airway disorder that affects approximately 9 million
children in the United States (1). It is caused by both genetic and environmental risk factors, and is
characterized by bronchoconstriction, which is the tightening of muscles surrounding the
bronchioles, inflammation and thickening as well as excessive mucous production of the airway
walls, and hyperresponsiveness to triggers such as allergens and air pollution (2, 4). Common
symptoms among asthmatic children include chest tightness, shortness of breath, wheezing and
coughing (2). These symptoms can lead to hospitalizations, ER visits, and school absences if the
disease is not managed. The severity of one’s asthma condition ranges widely depending on the
individual, environmental exposure, and the level of asthma management (2). Although it cannot
be cured, it can be controlled by careful management of the disease including the use of short acting
beta2-agonists and long-term control medicines (2).
Decreasing the prevalence of asthma or even the severity of asthma among children has
important public health implications since childhood asthma is the most common chronic condition
among children under the age of 18 (3). Moreover, asthma is not just a problem within the U.S. The
World Health Organization recognizes it as a worldwide public health problem (4). Because this
chronic disease is often under-diagnosed, WHO’s estimation of 235 million people with asthma is
most likely an underestimation (4).
Mild analgesic over-the-counter (OTC) medication use is common during pregnancy (6, 7).
It is known to reduce pain, fever, and inflammation. According to Werler et al, rates of mild
analgesic use during pregnancy are higher than during the 3 months prior to pregnancy, suggesting
that OTC drugs are used more during pregnancy (6). The top 10 medications that were taken in
pregnancy, in rank order, were acetaminophen (aka paracetamol), ibuprofen, pseudoephedrine,
aspirin, naproxen, diphenhydramine, guaifenesin, albuterol, amoxicillin, and dextromethorphan (6).
Other studies have also shown that acetaminophen is the most preferred and commonly used

analgesic and pyretic drug among pregnant mothers (5-9) since it is not associated with teratogenic
effects (8-11). One study approximates about two-thirds of pregnant mothers taking it at one point
during their pregnancy (6).
Within the past five decades, the increasing prevalence of acetaminophen use has paralleled
the increasing prevalence of asthma among children and adults (5- 7, 12-16), causing several
epidemiologists to question whether acetaminophen use poses a risk of asthma development. The
suspected association between acetaminophen and asthma development began in 1998, when
Varner et al. published one of the first studies, suggesting an epidemiological trend between
increased analgesics consumption and increased prevalence in asthma. The authors noted that the
rising asthma trend also coincided with the transition from aspirin to acetaminophen use, which
was precipitated by the discovery of aspirin's association with Reye's syndrome (5). Two years
later, Newson et al. supported this finding with an ecological analysis on multiple countries that
showed a positive correlation between the amount of acetaminophen consumption and prevalence
of asthma and other atopic conditions among both adults and children (13). Shaheen et al. also
published a population based case-control study, which demonstrated an association between
acetaminophen intake and asthma development in adults (17). In 2004, Barr et al. reported similar
results among women enrolled in a prospective study (18), and Koniman et al. discovered similar
results in a matched patient-sibling study in 2007 (12). In 2008, Beasley et al. reported a
statistically significant association between acetaminophen use during first year of life and the
development of asthma symptoms at the age of 6-7 years (19).
Furthermore, there is epidemiologic evidence that suggests a positive association between
intrauterine exposure to acetaminophen and the development of childhood asthma (20-25),
including a recent systematic review that concluded that acetaminophen use during pregnancy
increases the risk of childhood asthma (26). However, a recent rigorous prospective cohort study
suggests otherwise (27). Because both acetaminophen use during pregnancy and childhood asthma

are common, with asthma being a multi-factorial complex disease and acetaminophen being used
for several purposes, it has been challenging to confirm an association between prenatal
acetaminophen use and the risk of childhood asthma. Evidence of true association between
intrauterine exposure to acetaminophen and childhood development of asthma would have
important public health implications for pregnant women since acetaminophen is the
recommended pain-reliever and fever-reducer during pregnancy, and currently about two-thirds of
pregnant women take acetaminophen at some point during their pregnancy.
Our study conducted a more rigorous systematic review and meta-analysis in an attempt to
further clarify if prenatal acetaminophen is associated with physician-diagnosed childhood
asthma. Specifically, it addressed the question, "Among pregnant women, does acetaminophen use
compared with non-use increase the risk for physician-diagnosed asthma before the age of 10?" An
overall analysis was conducted prior to performing a pre-specified subgroup analysis, which
included age of child at diagnosis and stages of pregnancy.

Methods
Search Methods For Identification of Studies and Study Selection Criteria
PubMed search between the date of index start 1950 and December 1, 2011 was performed
to identify prospective cohort studies that examined the association between intrauterine exposure
to acetaminophen and asthma development during childhood. The search was restricted to English
language and human studies only. The following query string was used:
(acetaminophen[Title/Abstract] OR paracetamol[Title/Abstract] OR tylenol[Title/Abstract]) AND
(asthma[Title/Abstract] OR wheez*[Title/Abstract]) AND (pregn*[Title/Abstract] OR
child*[Title/Abstract] OR prenatal[Title/Abstract]).
The primary exposure of interest was acetaminophen (paracetamol) intake during
pregnancy (all trimesters included), and the primary outcome of interest was either physiciandiagnosed asthma or at least two symptoms (e.g. wheezing, emergency room visits, medication use
for asthma, etc) that suggest asthmatic condition among children younger than or at 10 years of
age. Studies were included based on the following criteria: 1) The study design was a prospective
cohort, 2) the primary exposure of interest was recorded 3) the primary outcome of interest was
recorded. Conversely, studies were excluded based on the following criteria: 1) The study design
was retrospective, cross-sectional, case-control, case series, or a case report, 2) the publication was
a review, guideline, or editorial, 3) the study was only available in abstract form 4) the study did not
have a clearly defined exposure or outcome, 5) "wheezing" was the only asthma-related outcome,
6) the study did not assess asthma prior to 10 years of age, 7) there was a lack of a reported
statistical measure of the association.
Searches were performed by one reviewer. Titles and then abstracts were evaluated and
rejected on initial screen based on the inclusion and exclusion criteria. Reference lists were also
reviewed for relevant studies. Each study included was scored, using the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) checklist, and studies were excluded

if they had <50% of STROBE checklist criteria. The Meta-analyses of Observational Studies in
Epidemiology (MOOSE) guidelines for conducting and reporting meta-analysis of observational
studies were also utilized. Study investigators were contacted if additional information or data was
required.
Data extraction and management
Data was extracted by one reviewer. The following values were extracted: authors' names,
study design, year of publication, sample size, average age of children, confounders that were
controlled for, estimated effect measure (preferably adjusted OR or adjusted RR), trimester, dose
and frequency of acetaminophen intake, number of children with asthma, number of women who
took acetaminophen during pregnancy.
Statistical significance at α level of 0.05 (or at 95%CI) for pooled estimates was calculated
using Review Manager (Revman) 5.1 (Cochrane Collaboration, Oxford, United Kingdom
[http://ims.cochrane.org/revman]). The inverse-variance fixed-effects model was used for metaanalysis calculation. Depending on the study, odds ratios or relative risks were recorded with
adjusted estimates taken preference over unadjusted estimates. These estimates were entered into
RevMan under the "Generic inverse variance" methodology for meta-analysis. Revman
automatically calculates the natural logarithm estimates and their standard errors. With these
calculations, RevMan produced a weighted average weight, utilizing the equation,
ΣYi(1/SEi2)/Σ(1/SEi2), where Yi is the intervention effect estimated in the ith study, SEi is the
standard error of that estimate, and the summation is across all studies (Cochrane Handbook,
9.4.3).
Heterogeneity was assessed using the I-squared statistic with low heterogeneity considered
as <50%, moderate heterogeneity between 50- 75%, and high heterogeneity >75%. Meta-analysis
was not conducted if heterogeneity was high. Since the I-squared statistic showed low to moderate
heterogeneity (<75%), sensitivity analysis was not performed to address heterogeneity problems.

Publication bias was assessed using funnel plots. Other potential biases included information bias
(e.g. recall bias) and selection bias due to attrition bias. Although it is difficult to detect information
bias, attrition bias was assessed by observing the response rate. Subgroup analyses stratified by
trimesters of exposure and age of diagnosis were also conducted. Sensitivity analysis was
performed to test any assumptions or decisions we encountered when creating the subgroups.

Results
Study Selection
The outcome of the literature review is shown in Figure 1. Eighty-five citations were
initially identified in the electronic search. Seventy-five studies were excluded after screening titles
and abstracts, and out of the ten potentially eligible prospective studies, only six of them met the
inclusion criteria after thorough review of the articles. Two studies were excluded because the
outcome studied did not qualify for inclusion criteria; both assessed wheezing as the only outcome
(30, 31). The other two studies were excluded since both studies extracted data from a previously
published study that was already included in this review (32, 33). The six studies that were
included in the review were all prospective studies, conducted during 2005~ 2010 across various
countries including the US, UK, Denmark, Norway and Sweden (Table 1; see Appendix I for more
details).
Bakkeheim et al. used a group of participants from a 10-year follow-up prospective birth
cohort, Environment and Childhood Asthma, in Oslo, Norway (34). 1,016 mothers were enrolled and
assessed for acetaminophen exposure with the use of a questionnaire throughout all three
trimesters and during the first 6 months since birth. A structured interview followed by a clinical
examination including pulmonary function tests, exercise test, skin prick test and blood test were
performed for each child at the age of 10 years. The primary outcomes were history of asthma and
symptoms and/or medication within the last year and/or positive exercise test. History of asthma
was defined as having at least 2 of the following criteria: physician-diagnosed asthma; dyspnea,
chest tightness and/or wheezing; and use of asthma medications.
Goksor et al. reported data from a prospective study consisting of 4, 496 participants in
Sweden (35). Prenatal acetaminophen exposure was obtained from a questionnaire that was given
when the child was 6 months of age. Because of the timing of the questionnaire, there is a
possibility of recall bias as it is possible for children to be diagnosed with asthma by the age of 6-

months. Supplemental data such as gender, gestational age, etc were also obtained from Swedish
Medical Birth Records. ‘Inhaled corticosteroids (ICS)-treated wheeze’ was used as a proxy for
physician-diagnosed asthma at the age of 4.5 years. Recurrent wheeze and episodic viral wheeze
were also recorded as separate outcomes.
Kang et al. recruited 1,505 pregnant mothers in southern New England, U.S. and followed
their children until the age of 6 years for physician-diagnosed asthma (27). Intrauterine
acetaminophen exposure (trimester, frequency and dose) was assessed through structured
interviews during first trimester of pregnancy, and postpartum (to assess for exposure during last
trimester of pregnancy). Secondary outcomes included wheezing, bronchitis, and allergy, with the
primary outcome being physician-diagnosed asthma ever with history of wheezing at age 6 years.
Persky et al. prospectively studied 345 pregnant women and their children who were
enrolled in a randomized controlled trial that assessed the effects of home visits by community
health educators and asthma-triggering environmental exposures in households (36). Pregnant
women participating in this study were enrolled and given a structured interview during their first
trimester. At age 1, children were assessed for the following outcomes: asthma diagnosis,
occurrence of any wheeze, wheeze that disturbed sleep, cough that disturbed sleep, emergency
department visits for respiratory problems, and hospitalization secondary to respiratory
problems. This study was conducted in Chicago, United States.
Rebordosa et al. followed 66,445 pregnant women and their children from the Danish
National Birth Cohort (37). One baseline questionnaire was given at enrollment, along with two
phone interviews during pregnancy, one parental phone interview when the child was 18 months
of age, and a final parental phone interview and questionnaire at the age of 7. In total, 66,445
children at age 18 months were interviewed and 12,733 children at age 7 years were interviewed.
The trimester, frequency and dose (only 2nd and 3rd trimester) of acetaminophen exposure were
recorded through a computerized telephone interview, which was given during gestational weeks

12 and 30, and respiratory outcomes were physician-diagnosed asthma, wheezing and
hospitalization due to asthma. Some of the data was also extracted from the participants’ unique
civil registration number, which is linked to the Danish National Hospital Registry.
Shaheen et al. utilized the population-based Avon Longitudinal Study of Parents and
Children in the county of Avon, England to study 8,511 pregnant women and their children (38).
Bristol district-residing women were eligible if their expected date of delivery fell within the time
frame of April 1, 1991 and December 31, 1992. Acetaminophen intake during pregnancy (both
trimester and frequency) was obtained from a questionnaire that was given during 18-20 weeks of
pregnancy and again at 32 weeks of pregnancy. Outcomes that were assessed when the child was
81 months old were the following: physician-diagnosed asthma, frequency of wheezing, hay fever,
eczema and atopy.
Table 2 displays the prevalence of intrauterine exposure to acetaminophen by studies. The
prevalence ranges widely from 3% to 70% with Bakkeheim et al. and Goksor et al. having the
lowest prevalence of 3% and 7.7%, respectively and the others having prevalences greater than
45%.
All six studies controlled for various confounders (Table 3). They calculated adjusted odds
ratio measurements with the exception of Bakkenheim et al. who presented their estimates as
unadjusted ORs, and Reberdosa et al. who presented their adjusted estimate measurements as
adjusted relative risks. While Goksor et al., Reberdosa et al. and Shaheen et al. found a statistically
significant association between prenatal acetaminophen intake and risk of childhood asthma,
Persky et al., Bakkenheim et al. and Kang et al. reported null results. Moreover, Kang et al.
suggested a protective effect when acetaminophen is ingested during both first and second
trimester of pregnancy [aOR(95%CI): 0.59(0.36, 0.98)].
Lastly, the review identified any study that included multiple children from the same
mother as independent enrollments and/or twins. Kang et al. excluded women from the analysis if

they had multiple births during the study enrollment period (April 1997- June 2000). Neither
Goksor et al. nor Persky et al. specified their method of adjusting for multiple births and twins.
Reberdosa et al. required that women give births to singletons, but did not address the issue of
multiple births. And both Shaheen et al. and Reberdosa et al. had a one year enrollment period,
which eliminated the possibility of multiple births from a single mother. However, they did not
address the concern of twins.
Estimated Effect Measurements
The pooled fixed-effects OR for all six studies was 1.12 (1.03, 1.22), (Fig. 2). Three studies
presented ORs within the stratified groups, but did not present the overall effect (33, 34, 37). Both
Shaheen et al. and Bakkeheim et al. calculated ORs for the different pregnancy stages of
acetaminophen exposure (0-20 weeks of pregnancy and 20-32 weeks of pregnancy; 1st and 2nd/3rd
trimesters, respectively). For both studies, the two pregnancy stages could not be collapsed into
one group since women who took acetaminophen throughout their entire pregnancy would be
accounted for twice. Consequently, we could not calculate the overall effect that acetaminophen
exposure during any period of pregnancy had on childhood asthma. Sensitivity analyses
demonstrated that while either of the two pregnancy groups in Bakkeheim et al.’s groups produced
the same overall pooled fixed-effects OR calculation for the six studies, Shaheen et al.’s ORs from the
two pregnancy stages produced slightly different pooled estimates. When we included Shaheen et
al.’s OR from the “0-20 weeks of pregnancy” group, we calculated the previously stated pooled
fixed-effects OR of 1.12 (1.03, 1.22). When we used the OR from the “20-32 weeks of pregnancy”
instead, we concluded with a pooled fixed-effects OR of 1.17 (1.07, 1.27). Finally, Reberdosa et al.
published two aORs that revealed the association between acetaminophen exposure during any
time of pregnancy and the risk of childhood development of asthma at ages 18 months and 7 years.
Instead of doing a sensitivity analysis, we used the OR from the group that was diagnosed with
asthma at 7 years of age since it is difficult to diagnose asthma among children under 6 (39).

The meta-analysis was stratified into studies that examined children under the age of 2
years and studies that diagnosed asthma in children over the age of 2. The age cut-off of 2 years
was selected as there was a clear division between two studies that assessed asthma in children at
ages 1 year and 18 months, and the rest of the studies that focused on children between the ages
4.5 years and 7 years. Reberdosa et al. conducted a longitudinal follow-up on children at ages 18
months and 7 years, and these two outcomes were analyzed separately.
Acetaminophen use during any stage of the entire pregnancy significantly increased the risk
of asthma in children under the age of 2 years, with a pooled fixed-effects OR of 1.18 (95%CI: 1.13,
1.23) (Fig. 3a). The subgroup analysis of acetaminophen intake during different trimesters showed
that acetaminophen intake during any one trimester was significantly associated with an increased
risk of asthma development in children (Fig. 3b). However, Persky et al.’s study reported a
statistically insignificant association between acetaminophen intake during 2nd and 3rd trimester
and childhood asthma. Intrauterine acetaminophen exposure during the first trimester of
pregnancy produced a statistically significant pooled OR of 1.15 (95%CI: 1.10, 1.20). Similarly
exposure during the second trimester of pregnancy resulted in a pooled OR of 1.13 (95%CI: 1.09,
1.17), and exposure during the third trimester of pregnancy resulted in a pooled OR of 1.17 (95%CI:
1.13, 1.21).
Acetaminophen use during any stage of the entire pregnancy significantly increased the risk
of asthma in children between ages 2- 10 years, with a pooled fixed-effects OR of 1.13 (95%CI: 1.01,
1.26) (Fig. 4a). The stratified analysis of acetaminophen intake during different stages of pregnancy
produced mixed results (Fig. 4b). There were no significant associations between acetaminophen
intake during the first two trimesters of pregnancy and asthma in offsprings. However,
acetaminophen intake during medium to late stages of pregnancy (a combination of 2nd and 3rd
trimester or 20-32 weeks of pregnancy) significantly increased the risk of asthma in children by
23% (pooled OR and 95%CI of 1.23[1.08, 1.42]). Lastly, intrauterine acetaminophen exposure

during the third trimester of pregnancy produced a statistically significant pooled OR of 1.16
(95%CI: 1.03, 1.30).
There was no evidence of high heterogeneity among the studies. The majority of I2
calculations resulted in 0% with the exception of I2= 31% in the overall pooled estimate of the six
studies, and 71% in the overall pooled estimate for asthma outcome in children over 2 years of age.
A variety of biases were noted (see Appendix I for more details). Because most of these
studies relied on self-report, incomplete ascertainment of exposure and outcome may have caused
information bias. However, recall bias was minimized by interviewing pregnant women during
pregnancy when the asthma outcome was yet to be determined, and the acetaminophen intake can
be more accurately reported. Detection bias was minimized by using physician-diagnosed asthma
as the primary outcome of interest. Selection bias due to attrition bias may have been a concern for
some of these studies as non-participants were noted to be different from the participants (Goksor
et al. 2011). Specifically, those who did not participate tended to smoke before pregnancy, have
preterm birth and have lower education. Even after stratifying the meta-analysis by study qualities
by excluding Goksor et al’s study, we concluded with a significant association of acetaminophen
ingestion during pregnancy and the risk of developing asthma during childhood years (OR[95%CI]:
1.10[1.01, 1.20]).
Lastly, in terms of publication bias, the funnel plot (Fig. 5) demonstrated a normal trend,
with findings from studies with smaller sample sizes found dispersed at the bottom of the funnel
and results from studies with larger sample sizes located toward the top of the funnel in the high
precision area. The plot indicated a slight trend to the right of the reference line, suggesting that
studies with insignificant or protective association were missing.

Discussion
Acetaminophen has been considered the preferred choice of over-the-counter pain-reliever
and fever-reducer medication during pregnancy (5-11, 44-47). It is labeled as FDA Category B
across all trimesters, indicating that animal studies have not demonstrated any fetal risk or if it has,
there have been no randomized controlled studies among pregnant women to prove this finding
(47). Guidelines for medication use during pregnancy have recommended using acetaminophen
minimally and only when necessary (44-46). Pregnant women should follow the dosage
instructions on the back of the medication package, and ingestion of acetaminophen should not
exceed the recommended dose of 4 grams a day (44- 46). Currently, we do not know how much
acetaminophen crosses the placenta.
Overall, prenatal acetaminophen exposure increases the risk of childhood asthma
development with a pooled fixed-effects OR (95 CI%) of 1.12 (1.03, 1.22). The studies were
subgrouped by age of asthma diagnosis (≤ 2 years vs. >2 years) as clinical diagnosis of asthma have
been reported to be more accurate as the child nears 6 years of age (39). The pooled fixed-effects
ORs for both subgroups were consistent with the overall estimate, with the subgroup estimates
being 1.13 (1.01, 1.26) and 1.18 (1.13, 1.23) for children being diagnosed with asthma at ages 2
years and above and less than 2 years, respectively.
These results are consistent with past reviews conducted by Etiman et al. and Eyers et al.
(26, 29). Etiman et al. (2009) had conducted a larger systematic review, which consisted of studies
that investigated acetaminophen exposure during pregnancy, childhood years, and adult years.
Although Etiman et al. demonstrated an association between acetaminophen use during pregnancy
and increased risk of childhood asthma with an OR (95%CI) of 1.28 (1.13-1.39), Eyers et al. (2011)
argued that there were several methodological problems. For instance, the outcome was not
standardized across all studies and the details necessary to assess the validity of this systematic
review were missing (29). Additionally, Etiman et al.’s systematic review was not focused solely on

prenatal acetaminophen use and risk of childhood asthma (29). Lastly, one of the ORs reported in
Etiman et al.’s paper is nowhere to be found in the original paper, and Etiman et al. used hazards
ratio for “hospitalization for asthma” instead of relative risk for “physician-diagnosed asthma” for
one of the selected studies (Reberdosa et al. 2008) (Table 4).
For the reasons stated above, Eyers et al. (2011) conducted a systematic review and metaanalysis, and concluded that acetaminophen use during pregnancy remained a risk factor for
childhood asthma development. However, there were several methodological limitations. First, only
studies that provided raw data were included in the review as the pooled summary estimate was
calculated utilizing unadjusted odds ratios from the raw data. Consequently, the authors neglected
to take into account confounders such as parental history of asthma, maternal age, antibiotic use,
smoking and alcohol status and child's gender. Additionally, by restricting studies to those that
provide raw data, the authors may have overlooked studies that may have otherwise qualified for
inclusion. Second, the authors defined 'wheeze in the past 12 months' as the primary outcome of
interest. The condition 'wheezing' is subjective to individual interpretation and may not accurately
capture those with asthma. Furthermore, this outcome may have included non-asthmatic children,
thereby overestimating the number of cases. Lastly, the inclusion criteria included a range of
observational studies, resulting in the inclusion of both prospective and cross-sectional studies.
This combination may have weakened the conclusion that would have been more viable if cross
sectional studies were removed from the review. Unlike prospective cohort studies, cross-sectional
studies do not establish temporality. Consequently, cross-sectional studies cannot establish
evidence of causality between acetaminophen use and risk of asthma development.
Table 4 compares and contrasts the studies that were selected for analysis in Eyers et al.,
Etiman et al. and this systematic review. Three out of the total six studies from Eyers et al.’s review
were included in the current review. However, this review utilized the adjusted OR while Eyers et
al. calculated the unadjusted OR from the raw data. Although three out of the total five studies from

Etiman et al.’s review were used, two of the estimates did not coincide with this review’s ORs.
While Etiman et al. recorded the hazard ratio for “hospitalization for asthma” from Reberdosa et
al.’s study, this review retrieved the relative risk for “physician-diagnosed asthma”. Also, Etiman et
al.’s OR from Shaheen et al.’s study was nowhere to be located in the original publication.
This meta-analysis showed a significant positive association between acetaminophen intake
during the later stages of pregnancy and risk of asthma diagnosis at ages 2 years and older.
Meanwhile, studies that recorded asthma outcome in children younger than 2 years of age
displayed an increased risk of childhood asthma when acetaminophen was ingested during any
trimester of one’s pregnancy. More studies need to be conducted to compare the different
trimesters to assess which trimester(s) produces the highest risk of childhood asthma.
There was surprisingly a wide range of prenatal acetaminophen-use prevalence rates
among the six studies. Although Bakkeheim et al. had a high response rate of 99.7%, the low
prevalence rate of acetaminophen use of 3% may have been due to information bias since mothers
were asked to recall their acetaminophen use during pregnancy when their child turned 6 months
old. Consequently, it is possible that mothers underreported their exposure to prenatal
acetaminophen use. Goksor et al. also had a low prevalence rate of 7.7%, however, this can be
explained by the low response rate of 55%, which caused selection bias. Goksor et al. reported that
non-responders tended to smoke during pregnancy, have preterm birth and have lower education
level. To determine if these two studies invalidated the pooled fixed-effects OR of 1.12 (1.03, 1.22),
sensitivity analysis was conducted. Excluding these two studies from the pooled fixed-effects OR
did not change the result as the newly calculated estimate was 1.10 (1.01, 1.20) when the OR from
Shaheen et al.’s “1-20 weeks of pregnancy” group was used, and 1.16 (1.06, 1.26) when the OR from
Shaheen et al.’s “20-32 weeks of pregnancy” group was used. The other five studies have
prevalence rates that were reasonably proximal to 66%, which was the recorded rate by a previous
study (6).

This meta-analysis has several strengths. First, we used a more stringent exposure and
outcome inclusion criteria for study selection compared to previous systematic reviews. We
narrowed our search to prospective studies, and we only included studies that reported physiciandiagnosed asthma or two of the three asthma conditions as outcomes. Second, unlike previous
meta-analyses, we took preference of adjusted estimates over unadjusted estimates when
calculating the pooled inverse variance fixed-effects OR. Third, all six studies had rigorous study
designs such that biases were minimized. Additionally, by looking into prenatal exposure to
acetaminophen, we were able to negate the possibility of reverse causality, which is a common
problem for studies that investigated the association between postnatal acetaminophen intake and
risk of asthma development. In reverse causality, it is difficult to prove the causality between
acetaminophen intake and asthma since those with asthma may be more likely to ingest
acetaminophen due to increased co-morbidities such as respiratory infections and headaches (4043). Fourth, our meta-analysis had low heterogeneity, allowing us to use fixed-effects to calculate
pooled estimates. Lastly, since Eyers et al.’s publication, one new study has been published and
included in this review.
Our study also has limitations. First, this systematic review did not look into randomized
controlled studies. However, randomized controlled studies that investigate the association of
prenatal acetaminophen use of risk of childhood asthma do not exist due to ethical reasons.
Consequently, we chose to review prospective cohort studies, which are the next preferred study
design. Second, we were unable to stratify the reported estimates by confounders as each study
adjusted for varying combination of confounders. Third, as with any study, there is a possibility of
residual confounding. For example, the reasons for ingesting acetaminophen during pregnancy
may be a confounder as mothers who have asthma may potentially be taking acetaminophen for
their asthma. Despite these limitations, we used a sound and rigorous methodology under the

condition given to us (e.g. RCTs not being available, studies adjusting for different confounders,
etc.).
In conclusion, this systematic review and meta-analysis supports previous studies and
meta-analyses (26, 29) that have reported an association between prenatal acetaminophen
exposure and increased risk of childhood asthma. Although Eyers et al. reported an increased risk
of childhood asthma due to prenatal acetaminophen use, an editorial on Eyers et al.’s findings
concluded “for the time being, there is no need to recommend any changes to the clinical practice”
(48). This review revisits this topic and underscores the importance of further investigation as this
review suggests that intrauterine acetaminophen exposure increases the risk of childhood asthma
by approximately 12%- 17%. This result has significant clinical implications as more than half of
pregnant women ingest acetaminophen, and asthma is the most prevalent chronic illness among
children. Future studies that look into the timing of acetaminophen intake during pregnancy will
further help mothers time their acetaminophen intake during pregnancy. Moreover, it would be
beneficial if studies investigate how frequency and dose of acetaminophen use during pregnancy
affects the risk of childhood asthma.
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Figure 1: Flow Chart for Identifying Studies

Table 1: Basic Characteristics of Included Studies
Publication
Country Population
Study
Year
Bakkeheim et al. 2010
Norway
Children 10 yrs
Goksor et al.
2011
Sweden
Children 4.5 yrs
Kang et al.
2009
US
Children 6 yrs
Persky et al.
2008
US
Children 1 yr
Children 18 mo and 7
Reberdosa et al. 2008
Denmark
yrs
Shaheen et al.
2005
UK
Children 6-7 yrs
a)
b)
c)
d)
e)

Acetaminophen
Dose/Frequency
No
No
Dose a and Frequency b
No
Dose c and Frequency d
Frequency e

# of tablets or doses of acetaminophen per day in a month
“none”, “1-7 days per month”, “8-14 days per month”, “more than 14 days (but not every day) per month”, and
“everyday”
Only for 2nd and 3rd trimester
Total # of weeks of acetaminophen exposure per trimester
“not at all”, “sometimes”, “most days”, “everyday”

Table 2: Prevalence of intrauterine exposure to acetaminophen by studies
Study

Percent of
mothers taking
acetaminophen
during pregnancy

Bakkeheim et al.
Goksor et al.
Kang et al.
Persky et al.
Reberdosa et al.
Shaheen et al.

3.0
7.7
69.0
70.0
53.9
46.3

Table 3: Estimates of Included Studies

Study or Subgroup
Shaheen et al. 2005 (1)
Rebordosa et al. 2008 (2)
Persky et al. 2008
Kang et al. 2009
Goksor et al. 2011
Bakkeheim et al. 2010 (3)

log[Odds Ratio]
0.0953
0.1398
0.47
-0.2744
0.47
0.0392

Odds Ratio
SE Weight IV, Fixed, 95% CI
0.0695
0.0612
0.7073
0.1839
0.2347
0.5004

Total (95% CI)
Heterogeneity: Chi² = 7.28, df = 5 (P = 0.20); I² = 31%
Test for overall effect: Z = 2.55 (P = 0.01)

39.2%
50.6%
0.4%
5.6%
3.4%
0.8%

Odds Ratio
IV, Fixed, 95% CI

1.10 [0.96, 1.26]
1.15 [1.02, 1.30]
1.60 [0.40, 6.40]
0.76 [0.53, 1.09]
1.60 [1.01, 2.53]
1.04 [0.39, 2.77]

100.0% 1.12 [1.03, 1.22]
0.2
0.5
1
2
5
Favours experimental Favours control

(1) 0-20 weeks of pregnancy; Pooled estimate was 1.17(1.07, 1.27) when 20-32 weeks of pregnancy was used instead.
(2) Children 7 years of age
(3) First trimester of pregnancy; The pooled estimate was the same even when the group, 2nd/3rd trimesters of pregnancy, was used instead.

Figure 2: Meta-analysis of all six studies

Figure 3: Meta-analysis of studies that diagnosed asthma in children < 2 years of age:
Odds Ratio
Odds Ratio
IV, Fixed, 95% CI
Study or Subgroup
log[Odds Ratio]
SE Weight IV, Fixed, 95% CI
Persky et al. 2008
0.47 0.7073 0.1% 1.60 [0.40, 6.40]
Rebordosa et al. 2008
0.1655 0.0221 99.9% 1.18 [1.13, 1.23]
Total (95% CI)

100.0% 1.18 [1.13, 1.23]

Heterogeneity: Chi² = 0.19, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 7.51 (P < 0.00001)

Figure 3a: Exposure during entire pregnancy

0.2
0.5
1
2
5
Favours experimental Favours control

Study or Subgroup
log[Odds Ratio]
2.4.1 Early pregnancy (1st trimester)
Persky et al. 2008
Rebordosa et al. 2008
Subtotal (95% CI)

Odds Ratio
SE Weight IV, Fixed, 95% CI

0.2624 0.4875
0.1398 0.0227

Odds Ratio
IV, Fixed, 95% CI

0.1% 1.30 [0.50, 3.38]
24.0% 1.15 [1.10, 1.20]
24.0% 1.15 [1.10, 1.20]

Heterogeneity: Chi² = 0.06, df = 1 (P = 0.80); I² = 0%
Test for overall effect: Z = 6.18 (P < 0.00001)
2.4.2 Medium pregnancy (2nd trimester)
Rebordosa et al. 2008
Subtotal (95% CI)

0.1222 0.0184

36.5% 1.13 [1.09, 1.17]
36.5% 1.13 [1.09, 1.17]

Heterogeneity: Not applicable
Test for overall effect: Z = 6.64 (P < 0.00001)
2.4.3 Medium to late pregnancy (2nd/3rd trimesters)
Persky et al. 2008
Subtotal (95% CI)

0.6931 0.6143

0.0% 2.00 [0.60, 6.67]
0.0% 2.00 [0.60, 6.67]

Heterogeneity: Not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2.4.4 Late pregnancy (3rd trimester)
Rebordosa et al. 2008
Subtotal (95% CI)

0.157 0.0177

39.4% 1.17 [1.13, 1.21]
39.4% 1.17 [1.13, 1.21]

Heterogeneity: Not applicable
Test for overall effect: Z = 8.87 (P < 0.00001)
Total (95% CI)

100.0% 1.15 [1.13, 1.18]

Heterogeneity: Chi² = 2.73, df = 4 (P = 0.60); I² = 0%
0.2
0.5
1
2
5
Test for overall effect: Z = 12.63 (P < 0.00001)
Favours experimental Favours control
Test for subgroup differences: Chi² = 2.67, df = 3 (P = 0.45), I² = 0%
Figure 3b: Exposure during different periods of pregnancy

Figure 4: Meta-analysis of studies that diagnosed asthma in children > 2 years of age:

Study or Subgroup
Goksor et al. 2011
Kang et al. 2009
Rebordosa et al. 2008
Total (95% CI)

log[Odds Ratio]

Odds Ratio
SE Weight IV, Fixed, 95% CI

0.47 0.2347 5.8%
-0.2744 0.1839 9.4%
0.1398 0.0612 84.8%

Odds Ratio
IV, Fixed, 95% CI

1.60 [1.01, 2.53]
0.76 [0.53, 1.09]
1.15 [1.02, 1.30]

100.0% 1.13 [1.01, 1.26]

Heterogeneity: Chi² = 6.93, df = 2 (P = 0.03); I² = 71%
Test for overall effect: Z = 2.13 (P = 0.03)

Figure 4a: Exposure during entire pregnancy

0.2
0.5
1
2
5
Favours experimental Favours control

Study or Subgroup
log[Odds Ratio]
1.3.1 Early pregnancy (1st trimester)
Bakkeheim et al. 2010
Kang et al. 2009
Rebordosa et al. 2008
Subtotal (95% CI)

Odds Ratio
SE Weight IV, Fixed, 95% CI

Odds Ratio
IV, Fixed, 95% CI

0.0392 0.5004 0.4% 1.04 [0.39, 2.77]
-0.3857 0.2837 1.1% 0.68 [0.39, 1.19]
0.1398 0.0662 20.1% 1.15 [1.01, 1.31]
21.6% 1.12 [0.99, 1.27]

Heterogeneity: Chi² = 3.28, df = 2 (P = 0.19); I² = 39%
Test for overall effect: Z = 1.74 (P = 0.08)
1.3.2 Early to medium pregnancy (0-20 weeks)
Shaheen et al. 2005
Subtotal (95% CI)

0.0953 0.0695 18.2% 1.10 [0.96, 1.26]
18.2% 1.10 [0.96, 1.26]

Heterogeneity: Not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
1.3.3 Medium pregnancy (2nd trimester)
Rebordosa et al. 2008
Subtotal (95% CI)

0.0583 0.0723 16.9% 1.06 [0.92, 1.22]
16.9% 1.06 [0.92, 1.22]

Heterogeneity: Not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
1.3.4 Medium to late pregnancy (2/3 trimesters or 20-32 weeks)
Bakkeheim et al. 2010
Shaheen et al. 2005
Subtotal (95% CI)

0 0.4937 0.4% 1.00 [0.38, 2.63]
0.2151 0.0705 17.7% 1.24 [1.08, 1.42]
18.1% 1.23 [1.08, 1.42]

Heterogeneity: Chi² = 0.19, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 3.02 (P = 0.003)
1.3.5 Late pregnancy (3rd trimester)
Kang et al. 2009
Rebordosa et al. 2008
Subtotal (95% CI)

-0.0943 0.3264 0.8% 0.91 [0.48, 1.73]
0.157 0.0601 24.4% 1.17 [1.04, 1.32]
25.2% 1.16 [1.03, 1.30]

Heterogeneity: Chi² = 0.57, df = 1 (P = 0.45); I² = 0%
Test for overall effect: Z = 2.52 (P = 0.01)
Total (95% CI)

100.0% 1.14 [1.07, 1.20]

Heterogeneity: Chi² = 6.78, df = 8 (P = 0.56); I² = 0%
0.2
0.5
1
2
5
Test for overall effect: Z = 4.28 (P < 0.0001)
Favours experimental Favours control
Test for subgroup differences: Chi² = 2.75, df = 4 (P = 0.60), I² = 0%
Figure 4b: Exposure during different periods of pregnancy
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Figure 5: Funnel plot of comparison: Prenatal acetaminophen use during entire pregnancy
(Children diagnosed with asthma >2 years of age).
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